AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30061051 — intervention group
Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel 16 μg (pilot cohort)
Number of subjects: 120
Study 30061051 — intervention group
Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel 47 μg (main cohort)
Number of subjects: 120
Study 30061051 — intervention group
Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel (after fourth dose)
Number of subjects: 120
Study 30061051 — intervention group
Group type: COMPARATOR
Intervention: Pfs25H-EPA/Alhydrogel (after third dose)
Number of subjects: 120
Study 30061160 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) patients
Number of subjects: 22828
Study 30061160 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-severe CAD patients
Number of subjects: 22828
Study 30061160 — intervention group
Group type: COMPARATOR
Intervention: Normal coronaries and non-obstructive CAD patients
Number of subjects: 22828
Study 30061279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Number of subjects: 0
Study 30061293 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS228
Number of subjects: 0
Study 30061293 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam
Number of subjects: 0
Study 30061367 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE68/ACE64 catheters
Number of subjects: 204
Study 30061429 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site monthly screenings of cardiovascular risk factors
Number of subjects: 38
Study 30061431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (2 mg/kg/day to 6 mg/kg/day in four daily doses)
Number of subjects: 45
Study 30061431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 45
Study 30061431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30061811 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG brain computer interface (BCI) training paradigm using a virtual reality interface over seven sessions spread over 4 months
Number of subjects: 15
Study 30062043 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention including reminders (audio and/or visual) and text message or automated phone call if a dose of medication is not taken within a pre-specified time frame.
Number of subjects: 57
Study 30062043 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)-based counseling program with a trained glaucoma counselor for 6 months.
Number of subjects: 57
Study 30062099 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback Riding
Number of subjects: 44
Study 30062099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 30062662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (doses ranging from 0.25 to 9 mg/m²)
Number of subjects: 407
Study 30062662 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 407
Study 30062746 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher opioid dose
Number of subjects: 199
Study 30062746 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid dose
Number of subjects: 199
Study 30063383 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided stereotactic body radiation therapy (SBRT) up to a dose of 24 Gy in three fractions in 1 week
Number of subjects: 20
Study 30064377 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation with driving pressure 1.5 atm
Number of subjects: 30
Study 30064377 — intervention group
Group type: COMPARATOR
Intervention: High frequency jet ventilation with driving pressure 2.5 atm
Number of subjects: 30
Study 30064378 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina Pectoris (AP)
Number of subjects: 2272
Study 30064378 — intervention group
Group type: COMPARATOR
Intervention: Unheralded Myocardial Infarction (MI)
Number of subjects: 2272
Study 30064378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2272
Study 30064401 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wP) 40 to 75 mg/m² in combination with oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Number of subjects: 28
Study 30064401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic cyclophosphamide (OMC) 50 mg twice a day
Number of subjects: 28
Study 30064405 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based adherence clubs (AC) for ART
Number of subjects: 84
Study 30064418 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression screening and treatment integrated into HIV care initiation
Number of subjects: 0
Study 30064453 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic hydroxyapatite-coated uncemented Symax hip stem
Number of subjects: 80
Study 30064457 — intervention group
Group type: COMPARATOR
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1476
Study 30064457 — intervention group
Group type: COMPARATOR
Intervention: Treated diabetes mellitus (DM)
Number of subjects: 1476
Study 30064457 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-HOMA-IR (insulin resistance)
Number of subjects: 1476
Study 30064457 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-HOMA-IR
Number of subjects: 1476
Study 30064457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphericity index
Number of subjects: 1476
Study 30064462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-operative imaging studies (radiograms taken during the first week after surgery)
Number of subjects: 100
Study 30064462 — intervention group
Group type: COMPARATOR
Intervention: Routine post-operative radiograms
Number of subjects: 100
Study 30064466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention administered through a smartphone app (CBIA)
Number of subjects: 174
Study 30064466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention administered through a smartphone app plus telephone conference calls (CBIA + TCC)
Number of subjects: 174
Study 30064466 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 174
Study 30064713 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy
Number of subjects: 0
Study 30064713 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern intensive therapy
Number of subjects: 0
Study 30064713 — intervention group
Group type: EXPERIMENTAL
Intervention: Excellent glycemic control
Number of subjects: 0
Study 30064713 — intervention group
Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy and modern intensive therapies (MDI or pumps)
Number of subjects: 0
Study 30064713 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern intensive therapy using pumps and CGM
Number of subjects: 0
Study 30064713 — intervention group
Group type: EXPERIMENTAL
Intervention: Least expensive intensive therapy
Number of subjects: 0
Study 30064841 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE Iliac Branch Endoprosthesis (IBE)
Number of subjects: 99
Study 30064986 — intervention group
Group type: EXPERIMENTAL
Intervention: BSG/ESGE guidelines for interruption of anticoagulation
Number of subjects: 529
Study 30064986 — intervention group
Group type: EXPERIMENTAL
Intervention: BSG/ESGE guidelines for resumption of anticoagulation
Number of subjects: 529
Study 30064986 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier resumption of DOAC
Number of subjects: 529
Study 30064986 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bridging
Number of subjects: 529
Study 30064986 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk procedures
Number of subjects: 529
Study 30064986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk procedures
Number of subjects: 529
Study 30064997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy protocol for tissue banking
Number of subjects: 0
Study 30064997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy protocol
Number of subjects: 0
Study 30065032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion during a mixed-nutrient meal
Number of subjects: 15
Study 30065032 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion during a mixed-nutrient meal
Number of subjects: 15
Study 30065032 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion) during a mixed-nutrient meal
Number of subjects: 15
Study 30065081 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient pulmonary rehabilitation
Number of subjects: 52
Study 30065100 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI3726 (ADCT-401), an antibody-drug conjugate targeting PSMA, consisting of an engineered anti-PSMA antibody J591 conjugated to the pyrrolobenzodiazepine (PBD) dimer tesirine.
Number of subjects: 0
Study 30065909 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-mother (CH-M) group, n=28
Number of subjects: 76
Study 30065909 — intervention group
Group type: EXPERIMENTAL
Intervention: Child alone (CH) group, n=25
Number of subjects: 76
Study 30065909 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group, n=23
Number of subjects: 76
Study 30065943 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment (3 weeks, 15 days of treatment, 120 to 150 minutes a day)
Number of subjects: 70
Study 30065943 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 70
Study 30066805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 seasonal influenza vaccine
Number of subjects: 299
Study 30066805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2014 seasonal influenza vaccine
Number of subjects: 299
Study 30066805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2015 seasonal influenza vaccine
Number of subjects: 299
Study 30067493 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) using single bolus propofol (mean dose 2.1 ± 0.3 mg/kg) and sevoflurane
Number of subjects: 36
Study 30067745 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral (DAA) therapy
Number of subjects: 1600
Study 30067754 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary force (MVF) assessment using a belt-stabilized hand-held dynamometer
Number of subjects: 123
Study 30067754 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle specific torque assessment
Number of subjects: 123
Study 30067754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynapenia assessment
Number of subjects: 123
Study 30067922 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect water-deprivation test
Number of subjects: 156
Study 30067922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion test (copeptin cutoff >4.9 pmol per liter)
Number of subjects: 156
Study 30067922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion test
Number of subjects: 156
Study 30067922 — intervention group
Group type: COMPARATOR
Intervention: Water-deprivation test
Number of subjects: 156
Study 30068263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide and low-dose dexamethasone
Number of subjects: 224
Study 30068263 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cMYC expression
Number of subjects: 224
Study 30068263 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRBN expression
Number of subjects: 224
Study 30068301 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective treatment with hypothermia
Number of subjects: 0
Study 30068301 — intervention group
Group type: COMPARATOR
Intervention: Registry of non-included eligible neonates
Number of subjects: 0
Study 30068379 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 18
Study 30068501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game intervention (played for at least 1 hour a day for 16 days)
Number of subjects: 60
Study 30068501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 30068505 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus lenalidomide (20 mg)
Number of subjects: 23
Study 30068615 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous skin-to-skin contact (SSC) for four consecutive days and nights in the family-room
Number of subjects: 50
Study 30068615 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-verified atrial fibrillation (AF)
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected AF
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obesity
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced estimated glomerular filtration rate
Number of subjects: 3706
Study 30068617 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one first-degree relative with AF
Number of subjects: 3706
Study 30068617 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 3706
Study 30068713 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 239
Study 30069230 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited psychodynamic psychotherapy
Number of subjects: 66
Study 30069230 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS (Psychodynamic Functioning Scales)
Number of subjects: 66
Study 30069230 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS
Number of subjects: 66
Study 30069308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle habits changes
Number of subjects: 62
Study 30069704 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially trial-eligible patients
Number of subjects: 285
Study 30069704 — intervention group
Group type: COMPARATOR
Intervention: Trial-ineligible patients
Number of subjects: 285
Study 30069758 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY 73-4506, Stivarga)
Number of subjects: 0
Study 30070030 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian men with overweight
Number of subjects: 20
Study 30070030 — intervention group
Group type: COMPARATOR
Intervention: White Caucasian men with overweight
Number of subjects: 20
Study 30070770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Number of subjects: 0
Study 30070770 — intervention group
Group type: EXPERIMENTAL
Intervention: Batefenterol (BAT)
Number of subjects: 0
Study 30070770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FF and BAT
Number of subjects: 0
Study 30070770 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of FF and BAT
Number of subjects: 0
Study 30071865 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076 250 mg orally once daily with continuous dosing in 4-week cycles until disease progression or unacceptable toxicity.
Number of subjects: 41
Study 30071991 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm using hs-cTnT
Number of subjects: 4368
Study 30071991 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm using hs-cTnI
Number of subjects: 4368
Study 30072107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 0
Study 30072107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30072203 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement surgery
Number of subjects: 16
Study 30072358 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Connected Web app-based intervention tailored to demographic characteristics and HIV/STI risk behaviors.
Number of subjects: 480
Study 30072358 — intervention group
Group type: COMPARATOR
Intervention: Control condition directing participants to AIDSVu.org testing site locator.
Number of subjects: 480
Study 30072410 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lead electrocardiogram
Number of subjects: 2171
Study 30072410 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure machine with atrial fibrillation detection algorithms
Number of subjects: 2171
Study 30072410 — intervention group
Group type: COMPARATOR
Intervention: Pulse-check
Number of subjects: 2171
Study 30072410 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests overall
Number of subjects: 2171
Study 30073261 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 143
Study 30073432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day for at least 7 consecutive days)
Number of subjects: 150
Study 30073497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with liver transplant
Number of subjects: 60
Study 30073497 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without liver transplant
Number of subjects: 60
Study 30073497 — intervention group
Group type: COMPARATOR
Intervention: Patients
Number of subjects: 60
Study 30073497 — intervention group
Group type: COMPARATOR
Intervention: Caregivers
Number of subjects: 60
Study 30073497 — intervention group
Group type: COMPARATOR
Intervention: Patients and caregivers
Number of subjects: 60
Study 30073583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg bid plus docetaxel 75 mg/m²
Number of subjects: 10
Study 30073583 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m²
Number of subjects: 10
Study 30073642 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) administered intravenously every 3 weeks until progression or unacceptable toxicity.
Number of subjects: 16
Study 30074085 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 80
Study 30074085 — intervention group
Group type: COMPARATOR
Intervention: Baermann funnel (BM)
Number of subjects: 80
Study 30074085 — intervention group
Group type: COMPARATOR
Intervention: Koga agar plate culture (KAP)
Number of subjects: 80
Study 30074111 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Blockers (BB)
Number of subjects: 972
Study 30074111 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE Inhibitors/Angiotensin Receptor Blockers (ACEi/ARB)
Number of subjects: 972
Study 30074259 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib 100 mg orally, once daily in continuous 28-day cycles from day -3, plus intravenous cytarabine 100 mg/m².
Number of subjects: 0
Study 30074259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine/daunorubicin (as part of the combination therapy).
Number of subjects: 0
Study 30074823 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS, JR augmented with additional KOOS items
Number of subjects: 1904
Study 30074823 — intervention group
Group type: COMPARATOR
Intervention: KOOS, JR
Number of subjects: 1904
Study 30074823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate score combining KOOS, JR and 4 KOOS Quality of Life subscale questions
Number of subjects: 1904
Study 30075748 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 10-15 days
Number of subjects: 858
Study 30075748 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 14 or 15 days
Number of subjects: 858
Study 30075748 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 10 days
Number of subjects: 858
Study 30075748 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily
Number of subjects: 858
Study 30075751 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 100
Study 30075751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 100
Study 30075808 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AS-related spinal radiographic alterations and obesity
Number of subjects: 204
Study 30075808 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-reactive protein (CRP)
Number of subjects: 204
Study 30075808 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 204
Study 30075808 — intervention group
Group type: EXPERIMENTAL
Intervention: High Bath Ankylosing Spondylitis Metrology Index (BASMI) and exposure to bisphosphonates during follow up
Number of subjects: 204
Study 30075808 — intervention group
Group type: EXPERIMENTAL
Intervention: mSASSS increase
Number of subjects: 204
Study 30075808 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of new syndesmophytes
Number of subjects: 204
Study 30076277 — intervention group
Group type: EXPERIMENTAL
Intervention: NGR-hTNF plus doxorubicin
Number of subjects: 28
Study 30076280 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-directed IFN-α treatment
Number of subjects: 0
Study 30076523 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 149
Study 30076946 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy group
Number of subjects: 27
Study 30076946 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 30077018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA-ND group
Number of subjects: 120
Study 30077018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA-D group
Number of subjects: 120
Study 30077018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 30077018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSA group
Number of subjects: 120
Study 30077125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks
Number of subjects: 89
Study 30077741 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30077990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitive troponin T (hs-TropT)
Number of subjects: 92
Study 30077990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging
Number of subjects: 92
Study 30077993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair with the MitraClip device
Number of subjects: 78
Study 30078410 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 0